iiinova — where your digital self keeps evolving

REPROCELL @reprocell.bsky.social · 06/03/2026

REPROCELL announces the launch of its 𝗨𝗦 𝗙𝗗𝗔-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗚𝗠𝗣 𝗠𝗖𝗕 𝗺𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝘀𝗲𝗿𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀, delivered from its Beltsville, Maryland facility. Read the press release: hubs.li/Q045mjWl0

000

REPROCELL @reprocell.bsky.social · 02/02/2026

The aim of our new AI-designed StemEdit gene editing platform is simple: make high-precision genome editing more reliable and reproducible for research and future clinical use. Reducing IP complexity and commercial risk helps developers move faster with confidence. www.reprocell.com/gene-editing...

000

REPROCELL @reprocell.bsky.social · 19/01/2026

Building scalable allogeneic cell therapies? 𝗙𝗿𝗼𝗺 𝗯𝗹𝗼𝗼𝗱 𝘁𝘆𝗽𝗲 𝘁𝗼 𝗛𝗟𝗔 𝗜/𝗜𝗜 𝗞𝗢 – 𝗰𝗼𝗺𝗽𝗮𝘁𝗶𝗯𝗶𝗹𝗶𝘁𝘆 𝗯𝘆 𝗱𝗲𝘀𝗶𝗴𝗻. REPROCELL's 𝗳𝗲𝗺𝗮𝗹𝗲 𝗛𝗟𝗔-𝗔 & 𝗛𝗟𝗔-𝗗𝗣𝗔𝟭, 𝗯𝗹𝗼𝗼𝗱 𝘁𝘆𝗽𝗲 𝟬+ 𝗵𝗼𝗺𝗼𝘇𝘆𝗴𝗼𝘂𝘀 𝗶𝗣𝗦𝗖 𝗹𝗶𝗻𝗲 (healthy 22-year-old donor) expands patient coverage and clinical flexibility. Learn more: hubs.li/Q03_gq6Y0

010

REPROCELL @reprocell.bsky.social · 07/01/2026

𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗶𝗻𝗴 𝗮𝗻 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗶𝗣𝗦𝗖-𝗱𝗲𝗿𝗶𝘃𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗮𝗻𝗱 𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝘀𝗰𝗮𝗹𝗲 𝗶𝘁 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗹𝘆? At REPROCELL, we offer 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆-𝗮𝗹𝗶𝗴𝗻𝗲𝗱, 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗚𝗠𝗣 𝗶𝗣𝗦𝗖 𝗠𝗖𝗕 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 with a unified workflow from donor to clinic, eliminating handoffs, delays, risk and complexity. Explore our services: hubs.li/Q03ZNzSX0

000

REPROCELL @reprocell.bsky.social · 17/12/2025

What if 𝗔𝗜 could design 𝗯𝗲𝘁𝘁𝗲𝗿 𝗴𝗲𝗻𝗲 𝗲𝗱𝗶𝘁𝗼𝗿𝘀 than what evolution gave us? 𝗢𝗽𝗲𝗻𝗖𝗥𝗜𝗦𝗣𝗥-𝟭 - the first AI-designed genome editing enzyme - might be exactly that. In our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴, we explain: ✔What OpenCRISPR-1 is & how it was created ✔Why developers should care 👉Read the 𝗯𝗹𝗼𝗴: hubs.li/Q03YjfQp0

010

REPROCELL @reprocell.bsky.social · 12/12/2025

🎉Congratulations to 𝗼𝘂𝗿 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗣𝗿𝗼𝗳𝗹𝘂𝗲𝗻𝘁 on their successful $𝟭𝟬𝟲𝗠 𝗿𝗮𝗶𝘀𝗲! Their latest funding round, led by Altimeter Capital and Bezos Expeditions - marks a major milestone in advancing 𝗔𝗜-𝗱𝗿𝗶𝘃𝗲𝗻 𝗽𝗿𝗼𝘁𝗲𝗶𝗻 𝗱𝗲𝘀𝗶𝗴𝗻 𝗳𝗼𝗿 𝘁𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, agriculture, and beyond. Find out more: hubs.li/Q03XR4ht0

hubs.li

Profluent bags $106m for AI-driven protein design tech

The Series B aims to fuel expansion into therapeutics, agriculture, and biomanufacturing applications.

000

REPROCELL @reprocell.bsky.social · 10/12/2025

Check out our GMP iPSC MCB services: - GMP iPSC MCB Services US: hubs.li/Q03X0fc-0 - GMP iPSC MCB Services Europe: hubs.li/Q03X0bv60

hubs.li

000

REPROCELL @reprocell.bsky.social · 05/12/2025

If you’re exploring 𝐚𝐥𝐥𝐨𝐠𝐞𝐧𝐞𝐢𝐜 𝐢𝐏𝐒𝐂-𝐝𝐞𝐫𝐢𝐯𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 and planning 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲-𝐬𝐜𝐚𝐥𝐞 𝐜𝐞𝐥𝐥 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠, our latest article, featured in BioInformant, gives a clear look at how REPROCELL can support your program with a regulatory-ready GMP iPSC MCB.⁣ 👉 Check out the article: hubs.li/Q03X0dK70

hubs.li

GMP Manufacturing of iPSC Master Cell Banks for Allogeneic Therapies at REPROCELL: A Cost-Optimized Approach | BioInformant

Are you advancing an iPSC therapy program and planning for clinical-scale manufacturing of GMP Master Cell Banks (MCBs)? REPROCELL provides industry-standard, GMP-compliant iPSC MCB manufacturing serv...

000

REPROCELL @reprocell.bsky.social · 03/12/2025

REPROCELL isn’t just another iPSC vendor. We’re an 𝗲𝗻𝗱-𝘁𝗼-𝗲𝗻𝗱 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 covering the entire journey in-house: donor sourcing, reprogramming, GMP MCB and gene-editing support for clinical programs. 𝗢𝗻𝗲 𝗽𝗮𝗿𝘁𝗻𝗲𝗿, 𝗼𝗻𝗲 𝘀𝘂𝗽𝗽𝗹𝘆 𝗰𝗵𝗮𝗶𝗻, 𝘇𝗲𝗿𝗼 𝗵𝗮𝗻𝗱𝗼𝗳𝗳𝘀. Learn more: hubs.li/Q03WBDmb0

000

REPROCELL @reprocell.bsky.social · 28/11/2025

Curious how to scale your iPSC-based therapy from bench to clinic? Check out the images 👇 to explore how REPROCELL delivers GMP-compliant iPSC MCB manufacturing - from donor sourcing and footprint-free reprogramming to full regulatory-ready cell banks under FDA/EMA/PMDA standards.

000

REPROCELL @reprocell.bsky.social · 26/11/2025

The recording of our recent webinar - “Innovative Cell Technologies to Bioengineer Human Tissues In Vitro for Use in R&D and Modelling Human Disease” with Prof. Stefan Przyborski, is now live! View the recording here 👉 hubs.li/Q03VW9Bz0 Explore our Alvetex® webpage: hubs.li/Q03VWjkS0

000

REPROCELL @reprocell.bsky.social · 21/11/2025

Our custom research iPSC service supports research-grade stem cell projects, spanning the full workflow from human donor sourcing to differentiated derivatives. Find out more: hubs.li/Q03Vm6GR0

000

REPROCELL @reprocell.bsky.social · 19/11/2025

In our latest blog, REPROCELL dives into how 𝗲𝘅𝗼𝘀𝗼𝗺𝗲𝘀 are emerging as 𝗰𝗲𝗹𝗹-𝗳𝗿𝗲𝗲 𝗮𝗹𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝘃𝗲𝘀 to conventional cell therapies. Read more on our blog: hubs.li/Q03TXHKp0 Check out REPROCELL's iPSC-derived Exosomes: hubs.li/Q03TXJ8j0

000

REPROCELL @reprocell.bsky.social · 14/11/2025

We’re excited to launch highly purified iPSC-derived exosomes for pre-clinical & advanced research, made at our Japan GMP facility. Derived from StemRNA™ clinical-grade iPSCs, available in liquid & lyophilized forms, ideal for anti-aging & collagen production studies. Learn more: hubs.li/Q03TbmM50

000

REPROCELL @reprocell.bsky.social · 12/11/2025

Advancing an iPSC therapy program? We offer GMP iPSC MCB manufacturing in the EU (via Histocell) and the US (REPROCELL USA). • EU (Histocell): hubs.li/Q03SMwJz0 • US (REPROCELL USA): hubs.li/Q03SMtVL0 Ready to discuss your project requirements? Submit an inquiry or email us: 𝗶𝗻𝗳𝗼-𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺

000

REPROCELL @reprocell.bsky.social · 03/11/2025

Join our webinar on 🗓️6 Nov 2025 with Prof. Stefan Przyborski: learn how Alvetex® scaffolds can help you build layered, human-relevant tissue models. 🕛 EMEA 12:00 UK / 13:00 CET 🕛 US 12:00 EST / 09:00 PST 👉Seats are filling fast, you can save your spot here: hubs.li/Q03P57jb0

000

REPROCELL @reprocell.bsky.social · 31/10/2025

REPROCELL is thrilled to have attended the 2025 Cell & Gene Therapy Symposium – Mid-Atlantic in Washington D.C., where researchers, clinicians and industry united to advance cell & gene therapies from discovery to patient care.

000

REPROCELL @reprocell.bsky.social · 30/10/2025

Join us on 𝟲 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 2025 for a webinar on 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗖𝗲𝗹𝗹 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 𝘁𝗼 𝗕𝗶𝗼𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿 𝗛𝘂𝗺𝗮𝗻 𝗧𝗶𝘀𝘀𝘂𝗲𝘀 𝙄𝙣 𝙑𝙞𝙩𝙧𝙤 𝗳𝗼𝗿 𝗨𝘀𝗲 𝗶𝗻 𝗥&𝗗 𝗮𝗻𝗱 𝗠𝗼𝗱𝗲𝗹𝗹𝗶𝗻𝗴 𝗛𝘂𝗺𝗮𝗻 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 with 𝗣𝗿𝗼𝗳. 𝗦𝘁𝗲𝗳𝗮𝗻 𝗣𝗿𝘇𝘆𝗯𝗼𝗿𝘀𝗸𝗶. 🕛 EMEA Session: 12:00 UK / 13:00 CET 🕛 US Session: 12:00 EST / 9:00 PST 🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 here: hubs.li/Q03Q0-hk0

000

REPROCELL @reprocell.bsky.social · 24/10/2025

We're excited to add a 23-year-old, Caucasian male (A⁺ blood type) donor line to our StemRNA™ clinical iPSC portfolio. Multiple iPSC clones from this donor are now ready for testing, the perfect foundation for advancing your cell therapy development. Explore more: hubs.li/Q03PSDPF0

000

REPROCELL @reprocell.bsky.social · 22/10/2025

Excited to share that thanks to the MSCRF Manufacturing Assistance grant, we’re building a full-scale GMP/CDMO facility (Maryland) for large-batch hiPSC-derived & MSC therapy manufacturing, turnkey services from banking and gene-editing to differentiation & production. Read more: hubs.li/Q03PGxWh0

000

REPROCELL @reprocell.bsky.social · 20/10/2025

We're excited to announce that REPROCELL & Histocell have jointly achieved AEMPS GMP certification for the manufacturing of 𝗶𝗣𝗦𝗖 𝗠𝗮𝘀𝘁𝗲𝗿 & 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗖𝗲𝗹𝗹 𝗕𝗮𝗻𝗸𝘀 using REPROCELL’s 𝗦𝘁𝗲𝗺𝗥𝗡𝗔™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀, produced at Histocell’s newly certified GMP facility in Spain. Learn more: hubs.li/Q03PgkGb0

000

REPROCELL @reprocell.bsky.social · 17/10/2025

In our recent webinar Dr Luana Ferrara showed how Qkine’s high-purity, animal-free growth factors & cytokines address reproducibility challenges in stem cell, organoid & disease models. Couldn’t join us live? The 𝗳𝘂𝗹𝗹 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴 is now online, on our 𝗬𝗼𝘂𝗧𝘂𝗯𝗲 channel → hubs.ly/Q03MVw-D0

000

REPROCELL @reprocell.bsky.social · 15/10/2025

𝗥𝗲𝗽𝗿𝗼 𝗠𝗦𝗖𝟭𝟬 now include 𝗢𝗻𝗰𝗼𝗣𝗮𝗻𝗲𝗹 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 at every stage — from donor fibroblasts → iPSCs → iMSCs. Get assurance of chromosomal integrity via G-band karyotyping + NGS-based variant screening across 400+ cancer-related genes. Check out Repro MSC10 here: www.reprocell.com/product-cata...

000

REPROCELL @reprocell.bsky.social · 10/10/2025

Thrilled to see REPROCELL featured by @bioinformant.bsky.social. From iPSCs, MSCs, and iMSCs, to MCB generation, clinical or research gene editing, we support your stem cell projects end-to-end.

000

REPROCELL @reprocell.bsky.social · 08/10/2025

𝗥𝗘𝗣𝗥𝗢𝗖𝗘𝗟𝗟 𝗨.𝗦.𝗔., 𝗜𝗻𝗰., has been awarded a 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗴𝗿𝗮𝗻𝘁 from the 𝗠𝗮𝗿𝘆𝗹𝗮𝗻𝗱 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗙𝘂𝗻𝗱 (𝗠𝗦𝗖𝗥𝗙), supporting life-saving stem cell research. Thanks to MSCRF & TEDCO — exciting updates are ahead! Find out more: www.tedcomd.com/news-events/...

tedcomd.com

Maryland Stem Cell Research Fund Awards $4.7 million to Support Innovations in Stem Cell Research | TEDCO

The grants will drive research and development programs in regenerative medicine across Maryland

000

REPROCELL @reprocell.bsky.social · 03/10/2025

🔥Could iMSCs be the future of burn care? A new study shows that iMSCs derived from iPSCs significantly accelerate healing of full-thickness burns in pigs — pointing to their potential in regenerative medicine. Study: hubs.li/Q03LTwgq0 Our iMSC products: hubs.li/Q03LTwc_0

hubs.li

Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing - npj Regenerative Medicine

npj Regenerative Medicine - Human iPSCs-derived mesenchymal stem cells promote skin regeneration and burn wound healing

000

REPROCELL @reprocell.bsky.social · 30/09/2025

REPROCELL now offers our gene-engineered 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖𝘀 (𝗕𝟮𝗠 𝗼𝗿 𝗱𝘂𝗮𝗹 𝗕𝟮𝗠 + 𝗖𝗜𝗜𝗧𝗔 𝗸𝗻𝗼𝗰𝗸𝗼𝘂𝘁𝘀) in combination with the unmodified parental StemRNA™ iPSC line—a bundle ideal for robust experimental design. 👉 𝗢𝘂𝗿 𝗶𝗣𝗦𝗖𝘀 𝗮𝗿𝗲 𝗯𝘂𝗶𝗹𝘁 𝗳𝗼𝗿 𝘁𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗺𝗲𝗱𝗶𝗰𝗶𝗻𝗲. 🌐 hubs.li/Q03GqzMM0

hubs.li

StemEdit Hypoimmune iPSCs

Discover REPROCELL's StemEdit™ hypoimmune iPSC lines, enabling advanced immune research and clinical applications with high-quality genome editing technology and regulatory-compliant cell lines.

000

REPROCELL @reprocell.bsky.social · 03/09/2025

What if the future of regenerative medicine is already here? In the last two years, the FDA approved three stem cell therapies—Ryoncil, Omisirge, and Lyfgenia—which push boundaries in immune repair, recovery, and rare diseases. Explore more: hubs.li/Q03GtPW90

hubs.li

Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025

Discover the latest advancements and FDA approvals in stem cell therapies, including iPSC and MSC treatments, reshaping the 2023-2025 clinical landscape.

000

REPROCELL @reprocell.bsky.social · 01/09/2025

GMP MCB Workflow — Part 2 Who? Our GMP stem cell team in Beltsville uses a closed system to produce iPSCs/iMSCs MCBs. What? We collect ethically consented skin biopsies, use footprint-free StemRNA™ technology, and expand to GMP MCBs. Why? Quality, speed, and scale for GMP MCBs.

000

REPROCELL @reprocell.bsky.social · 29/08/2025

Recombinant protein inconsistencies are quietly undermining reproducibility in stem cell, organoid & disease-modeling research. Want to find out more? Join our webinar: Raising the Standard: High-Quality & Reproducible Growth Factors for Advanced Cell Systems www.reprocell.com/resources/we...

000

REPROCELL @reprocell.bsky.social · 27/08/2025

Meet us at the Cell & Gene Meeting on the Mesa 2025 in Phoenix, AZ (Oct 6–8 in-person, Oct 9–10 virtual). Our stem cell expert, Joey, will be there to discuss our services. Connect: •MESA Partnering ONE (hubs.ly/Q03FMJWJ0) / Meeting request form (hubs.ly/Q03FMJ4q0) •𝗝𝗼𝘀𝗲𝗽𝗵.𝗥𝗼𝗴𝗲𝗿𝘀@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹𝘂𝘀𝗮.𝗰𝗼𝗺

000

REPROCELL @reprocell.bsky.social · 26/08/2025

𝗥𝗘𝗣𝗥𝗢𝗖𝗘𝗟𝗟'𝘀 𝗚𝗠𝗣 𝗠𝗖𝗕𝘀: 𝗪𝗵𝗼, 𝗪𝗵𝗮𝘁, 𝗪𝗵𝘆? 𝗣𝗼𝘀𝘁 𝗦𝗲𝗿𝗶𝗲𝘀 – 𝗣𝗮𝗿𝘁 𝟭 𝗪𝗵𝗼? REPROCELL’s global stem-cell team (USA & Europe). 𝗪𝗵𝗮𝘁? We deliver GMP MCBs (iPSC, iMSC, MSC), FDA/EMA/PMDA-compliant. 𝗪𝗵𝘆? Full-cycle service from donor sourcing to QC to delivery — seamless local support. Inquire: hubs.li/Q03Dzz-Q0

000

REPROCELL @reprocell.bsky.social · 22/08/2025

We are thrilled: our blog, “Why Early Genetic Variant Detection in iPSC Cultures Is Critical for Safe & Regulatory-Compliant Cell Therapies,” is now indexed on Google Scholar—boosting visibility for stem-cell researchers & cell-therapy developers. Read more: hubs.li/Q03CVhtJ0

000

REPROCELL @reprocell.bsky.social · 20/08/2025

MSCs lead regenerative medicine—1300+ clinical trials prove their anti-inflammatory, immunomodulatory & regenerative power. REPROCELL has your pipeline covered: -𝗚𝗠𝗣 & 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵‐𝗚𝗿𝗮𝗱𝗲 𝗠𝗦𝗖𝘀, 𝗶𝗠𝗦𝗖𝘀 -𝗦𝗲𝗰𝗿𝗲𝘁𝗼𝗺𝗲 & 𝗘𝘅𝗼𝘀𝗼𝗺𝗲 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝘀 🌐 Find out more: hubs.li/Q03CVgWp0 📩 Contact us: info‑us@reprocell.com

000

REPROCELL @reprocell.bsky.social · 18/08/2025

A New Bundle: StemEdit™ Hypoimmune iPSCs (HLA-Class I or I+II knockouts) plus unmodified matched StemRNA™ parental line (research/clinical-grade version). Visit: hubs.li/Q03D70k10 Contact: 𝗶𝗻𝗳𝗼-𝘂𝘀@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹𝘂𝘀𝗮.𝗰𝗼𝗺

000

REPROCELL @reprocell.bsky.social · 15/08/2025

Florida's new regulation allows MDs and DOs to administer stem cell treatments for ortho, wounds & pain without FDA IND approval, as long as the cells are sourced from 𝗙𝗗𝗔 𝗿𝗲𝗴𝗶𝘀𝘁𝗲𝗿𝗲𝗱, 𝗚𝗠𝗣 𝘀𝘁𝗮𝗻𝗱𝗮𝗿𝗱 facilities and 𝗶𝗻𝗳𝗼𝗿𝗺𝗲𝗱 𝗰𝗼𝗻𝘀𝗲𝗻𝘁 is provided. What are your thoughts? www.flsenate.gov/Committees/b...

000

REPROCELL @reprocell.bsky.social · 13/08/2025

We’re excited to share that scientists from REPROCELL Europe, in collaboration with Durham University, have developed a full-thickness human skin model using fibroblasts derived from iPSCs. Read the full news release here: hubs.li/Q03Cwqh70

000

REPROCELL @reprocell.bsky.social · 11/08/2025

What sets our StemRNA™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗲𝗲𝗱 & 𝗣𝗶𝗹𝗼𝘁 𝗶𝗣𝗦𝗖𝘀 apart? 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗦𝗲𝗲𝗱 𝗶𝗣𝗦𝗖𝘀: Clinical-grade iPSCs, ready for full-scale-up to GMP MCBs. 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗶𝗹𝗼𝘁 𝗶𝗣𝗦𝗖: iPSCs expanded from GMP-like Clinical Seed Clones, ideal for early-stage experimentation and method validation. Learn more: hubs.li/Q03C4mYz0

000

REPROCELL @reprocell.bsky.social · 06/08/2025

BioInformant's 2025 iPSC industry report recognizes REPROCELL among the top global iPSC competitors. We offer custom iPSC differentiation, off‑the‑shelf iPSC-derived human neurons & iMSCs, full-scale 𝗚𝗠𝗣 𝗶𝗠𝗦𝗖/𝗶𝗣𝗦𝗖/𝗠𝗦𝗖 𝗠𝗖𝗕 manufacturing. 🌐Explore: www.reprocell.com/services hubs.li/Q03BvwQc0

000

REPROCELL @reprocell.bsky.social · 04/08/2025

REPROCELL helps cell therapy developers with the right starting material and prepare for future regulatory filings - whether you are in the preclinical phase or ready to scale your stem cell therapy. ⬇️ Explore our Stem Cell Services: hubs.li/Q03B5BQJ0

000

REPROCELL @reprocell.bsky.social · 01/08/2025

Culture-acquired mutations hinder the success of iPSC-based therapies. Learn more on this topic and how REPROCELL integrates 𝗲𝗮𝗿𝗹𝘆 & 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 to ensure successful regulatory submissions and safe clinical translation. Read our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴: hubs.li/Q03zWt5n0

000

REPROCELL @reprocell.bsky.social · 31/07/2025

Have you thought about 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗶𝗻𝘁𝗲𝗴𝗿𝗶𝘁𝘆 𝗼𝗳 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖𝘀 yet? REPROCELL uses 𝗡𝗚𝗦‐𝗯𝗮𝘀𝗲𝗱 𝗼𝗻𝗰𝗼𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 across 𝟰𝟬𝟬+ 𝗰𝗮𝗻𝗰𝗲𝗿‐𝗿𝗲𝗹𝗮𝘁𝗲𝗱 𝗴𝗲𝗻𝗲𝘀. We provide oncogenetic reports and rare‑variant analysis (functional scores + ClinVar). Ready to review these? Email: 𝗶𝗻𝗳𝗼‐𝗲𝗺𝗲𝗮@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺

000

REPROCELL @reprocell.bsky.social · 28/07/2025

Building a cell therapy from the ground up? Start with the right foundation. REPROCELL’s 𝗦𝘁𝗲𝗺𝗥𝗡𝗔™ 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗶𝗣𝗦𝗖 𝗦𝗲𝗲𝗱 𝗖𝗹𝗼𝗻𝗲𝘀 are engineered for regulatory success - already included in IND filings & trusted by biopharma leaders worldwide. Explore our updated webpage: www.reprocell.com/clinical-ste...

Why researchers choose our clinical-grade iPSCs:

• Derived using proprietary, 𝗳𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁-𝗳𝗿𝗲𝗲 𝗺𝗥𝗡𝗔 𝗿𝗲𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝗺𝗶𝗻𝗴 technology
• Fully consented donor material with 𝗴𝗹𝗼𝗯𝗮𝗹 𝘁𝗶𝘀𝘀𝘂𝗲 𝘀𝗼𝘂𝗿𝗰𝗶𝗻𝗴
• Comprehensive QC, including 𝗸𝗮𝗿𝘆𝗼𝘁𝘆𝗽𝗶𝗻𝗴 + 𝗡𝗚𝗦 𝗼𝗻𝗰𝗼𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴
• 𝗙𝗗𝗔 Drug Master File (𝗗𝗠𝗙) available for US generated lines via a LOA
• Starting material for 𝗚𝗠𝗣 𝗠𝗖𝗕𝘀 & 𝗪𝗖𝗕𝘀 for cell therapy use
• Clinical & commercial 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 available

000

REPROCELL @reprocell.bsky.social · 18/07/2025

Looking for a 𝘀𝗮𝗳𝗲𝗿, 𝗳𝗮𝘀𝘁𝗲𝗿, and 𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 way to generate 𝗶𝗣𝗦𝗖𝘀? Why StemRNA™ 3rd-Generation Reprogramming Kit? • 𝗙𝗼𝗼𝘁𝗽𝗿𝗶𝗻𝘁-𝗳𝗿𝗲𝗲 iPSC reprogramming • 𝗛𝗶𝗴𝗵 iPSC formation 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 • 𝗔𝗰𝗰𝗲𝗹𝗲𝗿𝗮𝘁𝗲𝗱 𝘁𝗶𝗺𝗲𝗹𝗶𝗻𝗲 & no screening needed Read the blog: www.reprocell.com/blog/why-mrn...

000

REPROCELL @reprocell.bsky.social · 14/07/2025

REPROCELL's 𝗚𝗠𝗣 𝗳𝗮𝗰𝗶𝗹𝗶𝘁𝘆 in the 𝗨𝗦𝗔, is equipped with the 𝗕𝗶𝗼𝗦𝗽𝗵𝗲𝗿𝗶𝘅 𝗖𝘆𝘁𝗼𝗰𝗲𝗻𝘁𝗿𝗶𝗰® 𝗫𝘃𝗶𝘃𝗼 𝗦𝘆𝘀𝘁𝗲𝗺 𝗠𝗼𝗱𝗲𝗹 𝟮, a closed-system platform in compliance with GMP across all production stages to minimize contamination risks, enhance product sterility, and overall safety. Find out more: hubs.li/Q03x0B6q0

000

REPROCELL @reprocell.bsky.social · 07/07/2025

Why 𝗦𝘁𝗲𝗺𝗘𝗱𝗶𝘁 𝗵𝘆𝗽𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗶𝗣𝗦𝗖 𝗹𝗶𝗻𝗲𝘀 stand out? -Consistent HLA suppression. -𝗣𝗿𝗼𝗽𝗿𝗶𝗲𝘁𝗮𝗿𝘆 𝗦𝘁𝗲𝗺𝗘𝗱𝗶𝘁 𝗴𝗲𝗻𝗼𝗺𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴: precise, efficient & licensable. -𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝗴𝗿𝗮𝗱𝗲 𝗽𝗮𝗿𝗲𝗻𝘁 𝗹𝗶𝗻𝗲 line meets 𝗙𝗗𝗔/𝗘𝗠𝗔/𝗣𝗠𝗗𝗔. -𝗡𝗼 𝗹𝗶𝗰𝗲𝗻𝘀𝗲 𝗳𝗼𝗿 𝗯𝗮𝘀𝗶𝗰 𝘂𝘀𝗲; commercial/clinical licensing available. Learn more: hubs.li/Q03w11Cs0

000

REPROCELL @reprocell.bsky.social · 04/07/2025

𝗦𝗰𝗮𝗹𝗶𝗻𝗴 𝗶𝗣𝗦𝗖𝘀 is expensive and inconsistent. 𝗔𝗯𝗹𝗲 𝗕𝗶𝗼𝘁𝘁 𝘀𝗶𝗻𝗴𝗹𝗲-𝘂𝘀𝗲 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 (5–500 mL) use low-shear, delta-impeller stirring inside incubators for uniform, cost-effective expansion of iPSCs. Dive into our 𝗹𝗮𝘁𝗲𝘀𝘁 𝗯𝗹𝗼𝗴: www.reprocell.com/blog/able-bi... Contact us: 𝗶𝗻𝗳𝗼-𝘂𝘀@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺

000

REPROCELL @reprocell.bsky.social · 02/07/2025

Genetic variants acquired during long-term culture can undermine the safety & consistency of pluripotent stem cells. REPROCELL profiles >400 cancer genes via NGS–based 𝗢𝗻𝗰𝗼𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀, and reports high-impact variants. Find out more: hubs.li/Q03vzTBq0 hubs.li/Q03vzVYX0

000

Reposted by REPROCELL

BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 01/07/2025

REPROCELL’s StemRNA™ iPSC Seed Stock Clones for Seamless Translational Research -https://bioinformant.com/reprocells-ipsc-seed-stock-clones/ @reprocell.bsky.social

011

REPROCELL @reprocell.bsky.social · 30/06/2025

Discover REPROCELL’s StemRNA™ iPSC Seed Stocks featured in BioInformant: -Ethical, FDA/EMA/PMDA-aligned donor recruitment -Footprint-free mRNA reprogramming for safety & efficiency -Multi-modal QC -Off-the-shelf lines, including HLA homozygous options Read the article: hubs.li/Q03vdbRd0

010